Abstract
Autonomous parvoviruses are small, non-enveloped, lytic DNA viruses replicating in the nucleus of actively dividing mammalian cells of appropriate species and tissue origins. In contrast to AAV, the other main subgroup of parvoviruses, autonomous parvoviruses do not require the assistance of an auxiliary virus for productive infection and do not stably integrate in the cellular DNA. Therefore, autonomous parvoviruses are suitable vectors for mediating transient gene transduction in dividing target cells. Interestingly, some of these viruses possess a striking inherent oncotropism, which may render them particularly suitable as selective vehicles in the clinical context of cancer gene therapy. In this chapter, we will present a brief overview of the biology of autonomous parvoviruses. This topic will be followed by a description of the design and recent developments in the production and use of parvoviral vectors, with a particular emphasis on biosafety aspects. Finally, the risk assessment related to the production and use of parvoviral vectors will be discussed in last part of the chapter.
Keywords: Autonomous Parvovirus-Based Vectors, mammalian cells, DNA viruses, cancer gene therapy, oncotropism
Current Gene Therapy
Title: Risk Assessment of the Use of Autonomous Parvovirus-Based Vectors
Volume: 3 Issue: 6
Author(s): Francis Dupont
Affiliation:
Keywords: Autonomous Parvovirus-Based Vectors, mammalian cells, DNA viruses, cancer gene therapy, oncotropism
Abstract: Autonomous parvoviruses are small, non-enveloped, lytic DNA viruses replicating in the nucleus of actively dividing mammalian cells of appropriate species and tissue origins. In contrast to AAV, the other main subgroup of parvoviruses, autonomous parvoviruses do not require the assistance of an auxiliary virus for productive infection and do not stably integrate in the cellular DNA. Therefore, autonomous parvoviruses are suitable vectors for mediating transient gene transduction in dividing target cells. Interestingly, some of these viruses possess a striking inherent oncotropism, which may render them particularly suitable as selective vehicles in the clinical context of cancer gene therapy. In this chapter, we will present a brief overview of the biology of autonomous parvoviruses. This topic will be followed by a description of the design and recent developments in the production and use of parvoviral vectors, with a particular emphasis on biosafety aspects. Finally, the risk assessment related to the production and use of parvoviral vectors will be discussed in last part of the chapter.
Export Options
About this article
Cite this article as:
Dupont Francis, Risk Assessment of the Use of Autonomous Parvovirus-Based Vectors, Current Gene Therapy 2003; 3 (6) . https://dx.doi.org/10.2174/1566523034578104
DOI https://dx.doi.org/10.2174/1566523034578104 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Retinoid Related Molecules an Emerging Class of Apoptotic Agents with Promising Therapeutic Potential in Oncology: Pharmacological Activity and Mechanisms of Action
Current Pharmaceutical Design Characteristics of Brain Tumor Stem Cells and the Rationale for Applying Tyrosine Kinase Inhibitors as Potential Targeting Agents
Recent Patents on Regenerative Medicine Ornithine Decarboxylase Inhibition: A Strategy to Combat Various Diseases
Mini-Reviews in Medicinal Chemistry Drugs for AIDS
Mini-Reviews in Medicinal Chemistry Molecular Imaging of Brain Tumors Personal Experience and Review of the Literature
Current Molecular Medicine Next Generation Antineoplastic Agents: A Review on Structurally Modified Vinblastine (VBL) Analogues
Current Medicinal Chemistry Pentacyclic Triterpenoids and Their Saponins with Apoptosis-Inducing Activity
Current Topics in Medicinal Chemistry Pioglitazone Prevents Smoking Carcinogen-Induced Lung Tumor Development in Mice
Current Cancer Drug Targets Promises of Nanotechnology for Drug Delivery to Brain in Neurodegenerative Diseases
Current Nanoscience Neurological Disorders in Medical Use of <i>Cannabis</i>: An Update
CNS & Neurological Disorders - Drug Targets G Protein-Coupled Receptor Fusion Proteins in Drug Discovery
Current Pharmaceutical Design Subject Index To Volume 7
Current Pharmaceutical Biotechnology Protein Pool Maintenance During Oxidative Stress
Current Pharmaceutical Design Targeting Tumors with Small Molecule Peptides
Current Cancer Drug Targets Withdrawal Notice: Role, Significance and Association of microRNA-10a/b in Physiology of Cancer
MicroRNA From Multiple PAR1 Receptor/Protein Interactions to their Multiple Therapeutic Implications
Current Topics in Medicinal Chemistry Gene Therapy of Cancer Based on Interleukin 12
Current Gene Therapy Central Nervous System Neoplasms in Hong Kong: An Inscription of Local Studies
Current Cancer Therapy Reviews Editorial: [Hot Topic: The Role of Nuclear Medicine in the Management of Patients with Glioblastoma Multiforme]
Current Radiopharmaceuticals Hydrolyzed Rutin Decreases Worsening of Anaplasia in Glioblastoma Relapse
CNS & Neurological Disorders - Drug Targets